Ownership and insider activity for Mirum Pharmaceuticals, Inc. (MIRM): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
Mirum Pharmaceuticals, Inc. is a biopharmaceutical firm dedicated to discovering and commercializing groundbreaking therapies for serious rare and orphan conditions. Its lead experimental drug, LIVMARLI, an oral treatment, is currently undergoing trials for progressive familial intrahepatic cholestasis (PFIC), Alagille syndrome, and biliary atresia.
Price
| Price | $97.37 |
| Market Cap | $5.9B |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-09-02 | Howe Jolanda | S-Sale | 658 | $66K |
| 2026-09-01 | Peetz Christopher | M-Exempt | 30,000 | $88K |
| 2026-09-01 | Peetz Christopher | S-Sale | 8,312 | $815K |
| 2026-09-01 | Peetz Christopher | S-Sale | 21,688 | $2.1M |
| 2026-09-01 | Peetz Christopher | M-Exempt | 30,000 | $88K |
| 2026-08-18 | Howe Jolanda | M-Exempt | 40,000 | $251K |
| 2026-08-18 | Howe Jolanda | S-Sale | 40,000 | $4.0M |
| 2026-08-18 | Howe Jolanda | M-Exempt | 40,000 | $251K |
| 2026-08-11 | BJERKHOLT ERIC | S-Sale | 6,001 | $600K |
| 2026-08-10 | Peetz Christopher | M-Exempt | 20,000 | $59K |
Balance Sheet (10y)
| Year | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $52.0M | $12.0M | $142.1M | $31.3M | $28.0M | $286.3M | $222.5M | $296.7M |
| Short-term Investments | 0 | $104.7M | $89.7M | $125.2M | $123.7M | 0 | $57.8M | $86.6M |
| Receivables | 0 | 0 | 0 | $4.4M | $24.0M | $68.0M | $78.3M | $123.3M |
| Inventory | 0 | 0 | 0 | $1.5M | $5.6M | $22.3M | $22.4M | $24.9M |
| Total Current Assets | $52.0M | $119.4M | $236.3M | $166.6M | $190.2M | $387.5M | $392.8M | $549.7M |
| Property, Plant & Equipment | 0 | $3.7M | $3.2M | $2.5M | $2.3M | $2.0M | $9.8M | $10.6M |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Intangible Assets | 0 | 0 | 0 | $18.7M | $59.0M | $252.9M | $249.8M | $260.9M |
| Total Assets | $52.0M | $146.7M | $240.9M | $294.7M | $352.9M | $646.6M | $670.8M | $842.8M |
| Accounts Payable | $269000 | $3.4M | $3.2M | $9.2M | $8.7M | $7.4M | $14.6M | $9.6M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Current Liabilities | $2.4M | $13.1M | $18.5M | $42.6M | $64.7M | $87.1M | $126.6M | $205.8M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 | $306.4M | $308.1M | $309.8M |
| Total Liabilities | $62.3M | $16.4M | $68.8M | $174.4M | $210.9M | $398.0M | $445.1M | $528.1M |
| Retained Earnings | -$17.3M | -$69.9M | -$173.2M | -$257.2M | -$392.8M | -$556.2M | -$644.2M | -$667.5M |
| Total Equity | -$10.3M | $130.3M | $172.1M | $120.2M | $142.0M | $248.7M | $225.6M | $314.7M |
| Total Debt | 0 | $3.6M | $3.3M | $2.6M | $2.2M | $308.1M | $317.8M | $319.5M |
| Net Debt | -$52.0M | -$113.0M | -$228.6M | -$153.9M | -$149.5M | $21.8M | $37.4M | -$63.9M |
| Working Capital | $49.5M | $106.3M | $217.9M | $124.0M | $125.5M | $300.5M | $266.2M | $343.9M |
Financial Health
| Debt / Equity | -72.97 |
| Current Ratio | 2.86 |
| Piotroski F-Score | 6 |
| Altman Z-Score | 4.42 |
Profitability
| Return on Equity | -410.20% |
| Return on Invested Capital | -13.09% |
| Return on Assets | -82.32% |
| Gross Margin | 81.70% |
| Operating Margin | -17.42% |
| Net Margin | -139.18% |
Related companies: ACAD · ADMA · BLTE · DYN · LGND · PRAX · RARE
Explore sector: Healthcare · Biotechnology
More sections of MIRM: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks